ClinicalTrials.gg
Not yet recruitingNCT07170046Updated Sep 12, 2025

Predictive Value of CEA and ctDNA in Lung Cancer Recurrence

An observational study in Lung Carcinoma, sponsored by Guangdong Provincial People's Hospital. Not yet recruiting. Open to participants aged 15 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Guangdong Provincial People's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
100
Ages
15 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lung Neoplasms by Guangdong Provincial People's Hospital — 7 open to participants now, 7 under way, none of them phase 3. Lung Neoplasms · Guangdong Provincial People's Hospital.

Started
2025
with 2 others
Observational
9 of 12
4 open now
Registered
11th of 12
by date

Among the 12 studies in Lung Neoplasms by Guangdong Provincial People's Hospital, this one is one of 3 that started in 2025, is one of 9 observational ones, and was the 11th registered.

Lung Neoplasms

5,434 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

7 of the 12 studies in Lung Neoplasms by Guangdong Provincial People's Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 15 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lung Neoplasms by Guangdong Provincial People's Hospital, or all of them as a file.
02

Study summary

The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.

Read the detailed description

This study will collect two groups of cohorts: prospective and retrospective.

03

Conditions studied

  • Lung Carcinoma

Browse trials for

04

Who can participate

Ages eligible
15 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from Guangdong Provincial People's Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Preoperative CEA > 5mg/l
  2. MRD testing was conducted before the operation
  3. The primary lesion was resected through surgery
  4. There should be at least two CEA and MRD follow-up tests within 2 years after the operation
  5. Postoperative pathology confirmed it as a malignant lung tumor

Exclusion criteria

Exclusion Criteria:

  1. Those without available imaging records
  2. Patients with a history of malignant tumors within the past five years
  3. Patients with secondary lung cancer
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • retrospective cohort

    The clinical information of the population in this cohort was retrospectively collected.

  • prospective cohort

    The clinical information of the population in this cohort was prospectively collected.

06

What researchers measure

Primary outcomes

  1. Postoperative tumor recurrence or progression

    If the tumor recurs or progresses within 2 years, it will be marked as 1. If not, it will be marked as 0.

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Aug 2027, 22 months later.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 22 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2025
First posted
Sep 12, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07170046
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Sep 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion